Treatment of patients with Hepatitis C virus (HCV) has evolved considerably in the recent past. In terms of cost-effectiveness, initially a dual-treatment regimen of peginterferon alfa and ribavirin was favored. This regimen recommendation was then replaced by the triple-treatment strategy with the introduction of boceprevir and telaprevir. Now the FDA approval of interferon-free treatments such as Sofosbuvir, Ledipasvir, and Viekira Pak has given patients more treatment options. Despite the high economic cost of these new drugs, they display low rates of adverse events and may ultimately represent cost-effective treatment options because of the benefits they can offer HCV patients.
Hepatitis C cost-effectiveness of therapy
Hepatitis B cost-effectiveness of therapy
Hepatitis D cost-effectiveness of therapy
Hepatitis E cost-effectiveness of therapy
Hepatitis survival guide
Hepatitis B diagnostic criteria
Hepatitis E primary prevention
Hepatitis C classification